All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub
Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie,  and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
View on  

Important announcement

@US_FDA has granted approval to ziftomenib for the treatment of adults with relapsed/refractory NPM1-mutated AML, based on KOMET-001 data.

Read more: https://loom.ly/7eF157k
View all drug updates

More drug updates

VIEW ALL

Important announcement

@US_FDA  has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, a first-in-class CAR NK-cell therapy, for the treatment of hematologic malignancies, including R/R AML. Read more: https://loom.ly/uWn46Lw

Dec 10, 2025

Important announcement

@US_FDA has granted fast-track designation to CLN-049, a novel FLT3/CD3 bispecific T-cell engager, for the treatment of R/R AML. The designation is based on favorable phase I clinical trial data. Read more: https://loom.ly/CTJi6wo

Dec 3, 2025

Important announcement

Ziftomenib has been included in the @NCCN guidelines as a Category 2A recommended treatment option for adults with R/R #AML with NPM1 mutation. Read more: https://loom.ly/GuInuWU Find out more about the recent @US_FDA approval of ziftomenib: https://loom.ly/XAjY_jk

Nov 26, 2025

Important announcement

@US_FDA has granted orphan drug designation to M2T-CD33 (LTI-214), an investigational immunotherapy targeting CD33-positive leukemic cells, for the treatment of AML. The designation is based on favorable preclinical data. Read more: https://loom.ly/zhR5UjI

Nov 6, 2025